Strategies against human papillomavirus infection and cervical cancer

Journal of Microbiology

Volumn 42, Issue 4, 2004, Pages 255-266

  Jung, Woon Won ^a   Chun, Taehoon ^b   Sul, Donggeun ^c   Hwang, Kwang Woo ^d   Kang, Hyung Sik ^e   Lee, Duck Joo ^f   Han, In Kwon ^a,f  

^a MyGene Company   (South Korea)

^b Hanyang University   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Chung Ang University   (South Korea)

^e Chonnam National University   (South Korea)

^f Sungkyunkwan University   (South Korea)

Author keywords

Cervical cancer; Human papillomavirus; Risk group; Therapy; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; CIDOFOVIR; DNA VACCINE; HUMAN PAPILLOMAVIRUS VACCINE; PODOPHYLLIN; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANUS; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; GENOTYPE; HIGH RISK POPULATION; HUMAN; NONHUMAN; PENIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; SOUTH KOREA; UTERINE CERVIX CARCINOMA; VAGINA; VERRUCA VULGARIS; VIRAL GENE DELIVERY SYSTEM; VIRUS CARCINOGENESIS; VIRUS GENE; VIRUS RECOMBINANT; VIRUS VIRULENCE; VULVA; WART VIRUS;

ANAL CANAL; CLINICAL TRIALS; FEMALE; GENITALIA, FEMALE; GENITALIA, MALE; GENOTYPE; HUMANS; KOREA; MALE; MUCOUS MEMBRANE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; SEXUALLY TRANSMITTED DISEASES; SKIN; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIRAL VACCINES;

ANIMALIA; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS; VERRUCA;

EID: 12344250439     PISSN: 12258873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Adam, E., Z. Berkova, Z. Daxnerova, J. Icenogle, W.C. Reeves, and R.H. Kaufman. 2001. Papillomavirus detection: demographic and behavioral characteristics influencing the identification of cervical disease. Am. J. Obstet. Gynecol. 182, 257-264.
2. Allen, M., M. Kalantari, A. Ylitalo, B. Pettersson, B. Hagmar, L. Scheibenplug, B. Johansson, U. Petterson, and U. Gyllensten. 1996. HLA DQ-DR haplotype and susceptibility to cervical carcinoma: indications of increased risk for development of cervical carcinoma in individuals infected with HPV 18. Tissue Antigens 48, 32-37.
3. Andrei, G., R. Snoeck, J. Piette, P. Delvenne, and E. DeClercq. 1998. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol. Res. 10, 523-531.
4. Apple, R.J., T.M. Becker, C.M. Wheeler, and H.A. Erlich. 1995. Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma. J. Natl. Cancer Inst. 87, 427-436.
5. Baker, T.S., W.W. Newcomb, N.H. Olson, L.M. Cowsert, C. Olson, and J.C. Brown. 1991. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys. J. 60, 1445-1456.
6. Bonnez, W. and R.C. Richman. 1994. Papillomaviruses, p. 1630-1640. In G.L. Mandell, J.E. Bennett, and R. Dolin R (eds.), Nandell, Douglas, and Bennetts principles and practice of infectious diseases, 5th ed. Churchill Livingston, Philadelphia, Pennsylvania.
7. Bontkes, H.J., M. Van Duin, T.D. deGruijl, M.F. Duggan-Keen, J.M. Walboomers, M.J. Stukart, R.H. Vereheijen, T.J. Helmerhorst, C.J. Meijer, R.J. Scheper, F.R. Stevens, P.A. Dyer, P. Sinnott, and P.L. Stern. 1998. HPV 16 infection and progression of cervical intraepithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequences variants. Int. J. Cancer 78, 166-171.
8. Bontkes, H.J., T.D. deGruijl, J.M. Walboomers, J.T. Schiller, J. Dillner, T.J. Helmerhorst, R.H. Vereheijen, R.J. Scheper, and C.J. Meijer. 1999. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J. Gen. Virol. 80, 409-417.
9. Bosch F., M.M. Manos, N. Munoz, M. Sherman, A.M. Jansen, J. Peto, M.H. Shiffman, V. Moreno, R. Kurman, and K.V. Shah. 1995. Prevalence of human HPV in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87, 796-802.
10. Breitburd F., R. Kirnbauer, N.L. Hubbert, B. Nonnenmacher, C. Trin-Dinh-Desmarquet, G. Orth, J.T. Schiller, and D.R. Lowy. 1995. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69, 3959-3963.
11. Burd, E.M. 2003. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev. 16, 1-17.
12. Burk, R.D., P. Kelly, J. Feldman, J. Bromberg, S.H. Vermund, J.A. Deltovitz, and S.H. Landesman. 1996. Declining presence of cervicovaginal human papilllomavirus infection with age is independent of other risk factors. Sex Transm. Dis. 23, 333-341.
13. Calore, E.E., S.M.M. Pereira, and M.J. Cavaliere. 2001. Progression of cervical lesions in HIV-seropositive women: a cytological study. Diagn. Cytopathol. 24, 117-119.
14. Campo, M.S., G.J. Grindlay, B.W. O'Neil, L.M. Chandrachud, G.M. McGarvie, and W.F. Jarrett. 1993. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J. Gen. Virol. 74, 945-953.
15. Christensen, N.D., J.W. Kreider, N.M. Cladel, and D.A. Galloway. 1990. Immunological cross-reactivity to laboratory-produced HPV-11 virions of polysera raised against bacterially derived fusion proteins and synthetic peptides of HPV-6b and HPV-16. capsid proteins. Virology 175, 1-9.
16. Chua, K.L. and A. Hjerpe. 1996. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 77, 121-127.
17. Cubie, H.A., A.L. Seagar, G.J. Beattie, S. Monaghan, and A.R.W. Williams. 2000. A longitudinal study if HPV detection and cervical pathology in HIV infected women. Sex Transm. Infect. 76, 257-261.
18. Da Silva D.M., G.L. Eiben, S.C. Fausch, M.T. Wakabayashi, M.P. Rudolf, M.P. Velders, and W.M. Kast. 2001. Cervical cancer vaccines: emerging concepts and developments. J. Cell Physiol. 186, 169-182.
19. Dupuy, C., D. Buzoni-Gatel, A. Touze, D. Bout, and P. Coursaget. 1999. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal drain ing lymph nodes. J. Virol. 73, 9063-9071.
20. Emeny, R.T., C.M. Wheeler, K.U. Jansen, W.C. Hunt, T.M. Fu, J.F. Smith, S. MacMullen, M.T. Esser, and X. Paliard. 2002. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J. Virol. 76, 7832-7842.
21. Evander, M., I.H. Frazer, E. Payne, Y.M. Qui, K. Hengst, and N.A. McMillan. 1997. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J. Virol. 71, 2449-2456.
22. Evans, T.G., W. Bonnez, R.C. Rose, S. Koenig, L. Demeter, J.A. Suzich, D. O'Brien, M. Campbell, W.I. White, J. Balsley, and R.C. Reichman. 2001. A Phase 1 study of a recombinant virus-like particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis. 183, 1485-1493.
23. Favre, M. 1975. Structural polypeptides of rabbit, bovine, and human papillomaviruses. J. Virol. 15, 1239-1247.
24. Franco, E.L. 1995. Cancer causes revisited:human papillomavirus and cervical neoplasia. J. Natl. Cancer Inst. 87, 779-780.
25. Galloway, D.A. 2003. Papillomavirus vaccines in clinical trials. Lancet Infect. Dis. 3, 469-475.
26. Greenstone, H.L., J.D. Nieland, K.E. de Visser, M.L. De Bruijn, R. Kirnbauer, R.B. Roden, D.R. Lowy, W.M. Kast, and J.T. Schiller. 1998. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. USA 95, 1800-1805.
27. Giroglu, T., L. Florin, F. Schäfer, R.E. Stre, and M. Sapp. 2001. Human papillomavirus infection requires cell surface heparin sulfate. J. Virol. 75, 1565-1570.
28. Harro, C.D., Y.-Y.S. Pang, R.B.S. Roden, A. Hildesheim, Z. Wang, J.M. Reynolds, T.C. Mast, R. Robinson, B.R. Murphy, R.A. Karron, J. Dillner, J.T. Schiller, and D.R. Lowy. 2001. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93, 284-292.
29. Hines, J.F., S.J. Ghim, N.D. Christensen, J.W. Kreider, W.A. Barnes, R. Schlegel, and A.B. Jenson. 1994. Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination. Gynecol. Oncol. 55, 13-20.
30. Ho, G.Y., R. Bierman, L. Beardsley, C.J. Chang, and Burk RD. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338, 413-428.
31. Holowaty, P., A.B. Miller, and T.T. Rohan. 1999. Natural dysplasia of the uterine cervix. J. Natl. Cancer Inst. 91, 252-258.
32. Hummel, M., J.B. Hudson, and L.A. Laimins. 1992. Differentiation-induced and constitutive transcription of human papillomavirus type 31b in cell lines containing viral episomes. J. Virol. 66, 6070-6080.
33. Jacobs, M.V., P.J. Snijders, A.J. van den Brule, T.J. Heimerhorst, C.J. Meijer, and J.M. Walboomers. 1997. A general primer-mediated PCR enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J. Clin. Microbiol. 35, 791-795.
34. Jeon, S., B.L. Allen-Hoffman, and P.F. Lambert. 1995. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 69, 2989-2997.
35. Jin, X.W., J. Cash, and A.W. Kennedy. 1999. Human papillomavirus typing and the reduction of cervical cancer risk. Cleveland Clin. J. Med. 66, 533-539.
36. Joyce, J.G., J.-S. Tung, C.T. Przysiecki, J.C. Cook, E.D. Lehman, J.A. Sands, K.U. Jansen, and P.M. Keller. 1999. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J. Biol. Chem. 274, 5810-5822.
37. Kleter, B., L.J. van Doom, L. Schrauwen, A. Molijn, S. Sastrowijoto, J. TerSchegget, J. Lindeman, B. Ter Harmsel, M. Burger, and W. Quint. 1999. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol. 37, 2508-2517.
38. Kim, K.Y., L. Blatt, and M.W. Taylor. 2000. The effects of interferon on the expression of human papillomavirus oncogenes. J. Gen. Virol. 81, 695-700.
39. Kiviat, N.B. and L.A. Koutsky. 1993. Specific human papillomavirus types as the causal agents of most cervical intraepithelial neoplasia: implications for current views and treatment. J. Natl. Cancer Inst. 85, 934-935.
40. Koutsky, L.A., K.A. Ault, C.M. Wheeler, D.R. Brown, E. Barr, F.B. Alvarez, L.M. Chiacchierini, and K.U. Jansen. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645-1651.
41. Lizard, G., M.-J. De'mares-Poulet, P. Roignot, and P. Gambert. 2001. In situ hybridization detection of single-copy human papillomavirus on isolated cells using a catalyzed signal amplification system:GenPoint™. Diagn. Cytopathol. 24, 112-116.
42. Liu, W.J., K.N. Zhao, F.G. Gao, G.R. Leggatt, G.J. Fernando, and I.H. Frazer. 2001. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 20, 862-869.
43. Magnusson, P.K.E., P. Lichtenstein, and U.B. Gyllenstein. 2000. Heritability of cervical tumors. Int. J. Cancer 88, 698-701.
44. Meyers, C., M.G. Frattini, J.B. Hudson, and L.A. Laimins. 1992. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 257, 971-973.
45. Moscicki, A.B., J. Palefsky, G. Smith, S. Siboshski, and G. Schoolnik. 1993. Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. Obstst. Gynecol. 82, 578-585.
46. Muller, M., J. Zhou, T.D. Reed, C. Rittmuller, A. Burger, J. Gabelsberger, J. Braspenning, and L. Gissmann. 1997. Chimeric papillomavirus-like particles. Virology 234, 93-111.
47. Murray, P.R., K.S. Rosenthal, G.S. Kobayashi, and M.A. Pfaller. 2002. Papovaviruses, p. 460. In Medical Microbiology. Mosby Press, London, United Kingdom.
48. Okamoto, A., C.D. Woodworth, K. Yen, J. Chun, S. Isonishi, T. Nikaido, T. Kiyokawa, H. Seo, Y. Kitahara, K. Ochiai, and T. Tanaka. 1999. Combination therapy with podophyllin and vidarabine for human papillomavirus positive cervical intraepithelial neoplasia. Oncol. Rep. 6, 269-276.
49. Orth, G. and Favre, M. 1985. Human papillomaviruses. Biochemical and biologic properties. Clin. Dermatol. 3, 27-42.
50. Papanicolaou, G.N. 1949. A survey of actualities and potentialities of exfoliative cytology in cancer diagnosis. Ann. Intern. Med. 31, 661-674.
51. Philips, D.H., and M. NiShé. 1993. Smoking-related DNA adducts in human cervical biopsies. IARC Sci. Publ. 124, 327-330.
52. Quint, W.G.V., G. Scholte, L.J. Van Doorn, B. Kleeter, P.H.M. Smits, and J. Lindeman. 2001. Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF10 PCR and HPV genotyping. J. Pathol. 194, 51-58.
53. Roden, R.B., D.R. Lowy, and J.T. Schiller. 1997. Papillomavirus is resistant to dessication. J. Infect Dis. 176, 1076-1079.
54. Roden, R.B., W.H. Yutzy, R. Fallon, S. Inglis, D.R. Lowy, and J.T. Schiller. 2000. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270, 254-257.
55. Santin, A.D., P.L. Hermonat, A. Ravaggi, M. Chiriva-Internati, D. Zhan, S. Pecorelli, G.P. Parham, and M.J. Cannon. 1999. induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J. Virol. 73, 5402-5410.
56. Solomon, D., D. Davey, R. Kurman, A. Moriarity, D. Oconnor, M. Prey, S. Raab, M. Sherman, D. Wilbur, T. Wright, and N. Young. 2002. The 2001 Bethesda System. Terminology for reporting results of cervical cytology. JAMA 287, 2114-2119.
57. Syrjänen, K.J. 1996. Natural history of genital human papillomavirus infections, p. 189-206. In C. Lacey (ed.), Papillomavirus reviews. Leeds University Press, Leeds, United Kingdom.
58. Suzich, J.A., S.J. Ghim, F.J. Palmer-Hill, W.I. White, J.K. Tamura, J.A. Bell, J.A. Newsome, A.B. Jenson, and R. Schlegel. 1995. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA 92, 11553-11557.
59. Tomas, M., D. Pim, and L. Banks. 1999. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 18, 7690-7700.
60. Torrisi, A., A. Del Mistro, G.L. Onnis, F. Merlin, R. Bertorelle, D. Minucci and D. Colposcopy. 2000. Cytology and HPV testing in HIV-positive and HIV-negative women. Eur. J. Gynecol. Oncol. 21, 168-172.
61. Villa, L.L. 1997. Human papillomaviruses and cervical cancer. Adv. Cancer Res. 71, 321-341.
62. Walboomers, J.M.M., M.V. Jacobs, M.M. Manos, F.X. Bosch, J.A. Kummer, K.V. Shah, P.J.F. Snijders, J. Peto, C.J.L. Meijer, and N. Munoz. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19.
63. Yang, X., G. Jin, Y. Nakao, M. Rahimtula, M. Pater, and A. Pater, 1996. Malignant transformation of HPV-16 immortalized human endocervical cells by cigarette smoke condensate and characterization of multistage carcinogenesis. Int. J. Cancer 65, 338-344.
64. zur Hausen, H. 1999. Papillomaviruses in human cancers. Proc. Assoc. Am. Physicians 111, 581-587.